Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

961
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
961

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Electroacupuncture Protects Against Post-MI Heart Failure Through Autonomic Regulation and α7nAChR Activation.

Cardiology research and practice·2026
Same author

Vascular endothelial growth factor (VEGF)-related blood flow regulation and anti-inflammation in the protection of Danzhu Fuyuan Granules against cognitive impairment.

Metabolic brain disease·2026
Same author

Metabolic syndrome emerges after artificial selection for low baroreflex sensitivity.

CNS neuroscience & therapeutics·2018
Same author

The regulatory activities of plant microRNAs: a more dynamic perspective.

Plant physiology·2011
Same author

Complete genome sequence of the type strain Pseudomonas stutzeri CGMCC 1.1803.

Journal of bacteriology·2011
Same author

MyBioNet: interactively visualize, edit and merge biological networks on the web.

Bioinformatics (Oxford, England)·2011

Related Experiment Video

Updated: Jun 9, 2025

Brain Slice Biotinylation: An Ex Vivo Approach to Measure Region-specific Plasma Membrane Protein Trafficking in Adult Neurons
06:18

Brain Slice Biotinylation: An Ex Vivo Approach to Measure Region-specific Plasma Membrane Protein Trafficking in Adult Neurons

Published on: April 3, 2014

12.9K

The Dopamine Transporter Is a New Target for Ischemic Stroke.

Yan-Qiong Cheng1, Ruo-Xi Zhang1, Xing-Yuan Li1

  • 1Department of Pharmacy Research, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

CNS Neuroscience & Therapeutics
|October 29, 2024
PubMed
Summary

Inhibition of the dopamine transporter (DAT) may protect against ischemic stroke by restoring synaptic function and preventing neuron death. Dopamine and its D1 receptor play key roles in this neuroprotective effect.

Keywords:
D1 receptordopaminedopamine transporterischemic strokeminiature excitatory postsynaptic currentminiature inhibitory postsynaptic current

More Related Videos

AAV Systems and Mouse Models for Investigating Ectopic Expression of Neurod1 in Transduced Cells at Subacute and Chronic Times Post-Ischemic Stroke
05:40

AAV Systems and Mouse Models for Investigating Ectopic Expression of Neurod1 in Transduced Cells at Subacute and Chronic Times Post-Ischemic Stroke

Published on: November 29, 2024

405
Evaluating Cell Death Signaling by Immunofluorescence in a Rat Model of Ischemic Stroke
11:32

Evaluating Cell Death Signaling by Immunofluorescence in a Rat Model of Ischemic Stroke

Published on: January 3, 2025

686

Related Experiment Videos

Last Updated: Jun 9, 2025

Brain Slice Biotinylation: An Ex Vivo Approach to Measure Region-specific Plasma Membrane Protein Trafficking in Adult Neurons
06:18

Brain Slice Biotinylation: An Ex Vivo Approach to Measure Region-specific Plasma Membrane Protein Trafficking in Adult Neurons

Published on: April 3, 2014

12.9K
AAV Systems and Mouse Models for Investigating Ectopic Expression of Neurod1 in Transduced Cells at Subacute and Chronic Times Post-Ischemic Stroke
05:40

AAV Systems and Mouse Models for Investigating Ectopic Expression of Neurod1 in Transduced Cells at Subacute and Chronic Times Post-Ischemic Stroke

Published on: November 29, 2024

405
Evaluating Cell Death Signaling by Immunofluorescence in a Rat Model of Ischemic Stroke
11:32

Evaluating Cell Death Signaling by Immunofluorescence in a Rat Model of Ischemic Stroke

Published on: January 3, 2025

686

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • The dopamine transporter (DAT) regulates dopamine homeostasis and is linked to nervous system diseases.
  • Its role in protection against ischemic stroke remains largely unknown.

Purpose of the Study:

  • To investigate the involvement of DAT in ischemic stroke.
  • To explore the potential of DAT inhibition as a therapeutic strategy.

Main Methods:

  • In vivo microdialysis to measure dopamine levels in ischemic mouse brains.
  • Utilized Slc6a3 (DAT gene) mutation and overexpression mouse models subjected to middle cerebral artery occlusion (MCAO).
  • Administered levodopa (Madopar) and nomifensine, and assessed synaptic function (mEPSCs, mIPSCs) and neuronal survival.

Main Results:

  • MCAO increased dopamine levels; Slc6a3 mutation reduced injury, while DAT overexpression worsened it.
  • Nomifensine and Madopar demonstrated neuroprotective effects.
  • Slc6a3 mutation and dopamine restored synaptic function and neuronal survival, effects blocked by D1 receptor antagonist SCH-23390.

Conclusions:

  • DAT inhibition presents a potential strategy for preventing ischemic stroke.
  • Dopamine and its D1 receptor are crucial for restoring synaptic function and protecting neurons during stroke.